AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02805725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1: Trabectedin
Description: Phase I trial based on a dose escalating study design (3+3 traditional design) assessing four dose levels of Trabectedin in combination with metronomic cyclophosphamide (CP).~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Study NCT03351452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal transcranial direct current stimulation
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
Study NCT03351452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real transcranial alternating current stimulation
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
Study NCT02805725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2: Trabectedin
Description: Patients will be included in a single-arm phase II trial. Administrated dose will be the RP2D defined in the dose escalation part of the trial. The design will follow a two-stage Simon's optimal design.~All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial.
Study NCT02805725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1: Cyclophosphamide
Description: A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
Study NCT02805725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2: Cyclophosphamide
Description: All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.
Study NCT04699734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine 1%
Description: Nerve block
Study NCT04699734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 9mg/ml
Description: Nerve block
Study NCT01099163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tonalin SG1000T FFA
Study NCT01099163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tonalin SG1000T FFA
Study NCT01493557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: 40 mg q.a.m, p.o.
Study NCT01493557 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pradaxa (dabigatran etexilate)
Description: 150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
Study NCT01493557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pradaxa, within 30 minutes after a meal
Description: Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
Study NCT01493557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pradaxa (dabigatran etexilate)
Description: 150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
Study NCT01910909 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
Study NCT02656420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout-derived Beverage
Description: Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.
Study NCT02656420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo as comparison to broccoli sprout-derived beverages
Study NCT01062945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching administration of a placebo pill.
Study NCT01062945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
Study NCT01580280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation
Description: Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
Study NCT01580280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-thrust Mobilization and Exercise
Description: Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
Study NCT01882218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galactose
Description: After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
Study NCT01882218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard liver surgery.
Study NCT03707509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Maximum 6 cycles for combined therapy. Camrelizumab maintenance.
Study NCT03707509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Maximum 6 cycles for combined therapy.
Study NCT03707509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.
Study NCT03707509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.
Study NCT03707509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.
Study NCT03707509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.
Study NCT03272568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant FVIII Fc fusion product Eloctate
Description: Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
Study NCT03272568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant FIX Fc fusion product Alprolix
Description: Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
Study NCT03272568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-operated diagnostic device for anemia AnemoCheck.
Description: Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
Study NCT01332565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 50mg tablet
Study NCT02772523 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle recommendations
Description: Dietary, and physical, cognitive and social activity recommendations
Study NCT02513186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02513186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous
Study NCT02513186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02513186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous
Study NCT02513186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous
Study NCT00659893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical gel
Description: 0.05%, two day dose
Study NCT03538353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pain education video
Description: The video was made for the DOD and VHA to educate their soldiers and veterans about chronic pain.
Study NCT02607553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Description: G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
Study NCT01916863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 400 mg
Study NCT01916863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 400 mg
Study NCT01916863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 400 mg
Study NCT01916863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: canagliflozin 300 mg
Study NCT01916863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canagliflozin 300 mg
Study NCT01916863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: canagliflozin 300 mg
Study NCT01916863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 Placebo
Study NCT01916863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 Placebo
Study NCT01916863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 Placebo
Study NCT03876171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Haitian youth family-based intervention study: family functioning
Description: A weekly group therapy with the youth in presence of a parent or caretaker in the family.
Study NCT03876171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Haitian youth intervention study: youth psychoeducational
Description: Weekly one and one psychoeducational module will be delivered to the youth.
Study NCT03876171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Haitian family-based intervention study: psychoeducational
Description: Weekly psychoeducational module will be delivered to the adolescent to the youth in the presence of a family.
Study NCT03876171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diversion Programs
Description: Youth will attend individual psychological counselling at an assigned Juvenile Services Department (JSD) diversion program.
Study NCT00125879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg qow or 40 mg/kg qow
Study NCT03218462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment (SADE)
Description: No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
Study NCT03516851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Precision bypass group
Description: With the brain cortex exposed after craniotomy, an initial ICG fluorescence angiography will be performed. ICG fluorescence angiography using Flow800 software to determine blood flow velocity and cortical perfusion in different candidate receptors. And electromagnetic neuronavigation system is used to evaluate the cerebral flow under different candidate recipient vessels. The treatment planning station will be situated based on the multimodal neuronavigation data. The vessel was chose as the receptor with lower flow velocity and lower cerebral perfusion area to perform anastomosis. Then a direct bypass surgery will be performed just like in the empirical direct bypass surgery group.
Study NCT02112435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnyx ®
Description: Active mandibular advancement splint
Study NCT02112435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narval ORM ® or SomnoDent ®
Description: Mandibular advancement splint
Study NCT01170039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: Lubiprostone will be given as 24 mcg orally twice a day.
Study NCT01170039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo pill will be given twice a day for 8 weeks.
Study NCT03763851 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Active PPP005
Description: Group assigned to active PPP005 in the randomized placebo-controlled trial
Study NCT03763851 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Palliative RadioTherapy to the symptomatic site
Study NCT03351452 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial electric current stimulation
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
Study NCT03290885 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined contact aspiration/Stent Retriever Technique
Description: Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid
Study NCT03290885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent retriever technique
Description: The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA.~A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion.~After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter.
Study NCT01303016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chispuditos
Description: Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
Study NCT01896219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation station (IMACTIS-CT®)
Study NCT01896219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: Reference method for gestures (carried out under CT) guidance
Study NCT02648919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noni extract
Description: Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
Study NCT03252431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: single dose pre-filled syringe
Study NCT03252431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta
Description: single dose pre-filled syringe
Study NCT02065037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: room temperature air insufflation
Description: control arm
Study NCT02065037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: warmed carbon dioxide insufflation
Description: comparator arm
Study NCT01444612 — intervention group
Intervention type: DRUG
Intervention: dalteparin
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
Study NCT01444612 — intervention group
Intervention type: DRUG
Intervention: enoxaparin
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
Study NCT01444612 — intervention group
Intervention type: DRUG
Intervention: fondaparinux
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
Study NCT01444612 — intervention group
Intervention type: DRUG
Intervention: unfractionated heparin
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
Study NCT02812342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib ointment
Description: Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
Study NCT04057950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cosmetic product
Description: Disulfure de sélénium versus placebo formula
Study NCT04057950 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cosmetic product
Description: Disulfure de sélénium versus placebo formula
Study NCT03337477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
Study NCT03337477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate(ZS)
Description: Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
Study NCT03337477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
Study NCT03337477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose 25g administered IV \<15 minutes before the insulin.
Study NCT03337477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
Study NCT03337477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Glucose 25g administered IV \<15 minutes before the insulin.